Campylobacteriosis

Is it okay to kiss your pet? The risk of animal-borne diseases is small, but real

Retrieved on: 
Monday, September 4, 2023
Salmonellosis, Infection, Human, Food, Rabies virus, Bird, Disease, Toxoplasma gondii, Parasitism, Prevalence, Bartonella henselae, Face, Aerosol, Turtle, Campylobacteriosis, Dog, Toxoplasmosis, MRSA, Biting, Fungus, Hygiene, Cat, Thought, Mycobacterium, Giardiasis, Animal, Soil, Population, Psittacosis, Risk, Water, Pet, Rabies, Bacteria, Genetically modified bacteria, Birth, Death, Scratch, Virus, Meningitis, Pneumonia, Mouth, Saliva, Pet industry, Medical imaging, Vaccine, Trapping, Veterinary medicine, Animal husbandry, Pig, Poultry farming, Toy, Zoonosis

Pet ownership is at an all-time high, with a recent survey finding 69% of Australian households have at least one pet.

Key Points: 
  • Pet ownership is at an all-time high, with a recent survey finding 69% of Australian households have at least one pet.
  • We spend an estimated A$33 billion every year on caring for our fur babies.
  • But some, such as pregnant people and those with weakened immune systems, are at greater risk of getting sick from animals.

What diseases can pets carry?

    • Infectious diseases that move from animals to humans are called zoonotic diseases or zoonoses.
    • Zoonoses can be transmitted directly from pets to humans, such as through contact with saliva, bodily fluids and faeces, or indirectly, such as through contact with contaminated bedding, soil, food or water.
    • Both dogs and cats are also reservoirs for methicillin-resistant bacterium Staphylococcus aureus (MRSA), with close contact with pets identified as an important risk factor for zoonotic transmission.
    • Read more:
      Cats carry diseases that can be deadly to humans, and it's costing Australia $6 billion every year

Birds, turtles and fish can also transmit disease

    • Pet birds can occasionally transmit psittacosis, a bacterial infection which causes pneumonia.
    • Contact with pet turtles has been linked to Salmonella infections in humans, particularly in young children.
    • Even pet fish have been linked to a range of bacterial infections in humans, including vibriosis, mycobacteriosis and salmonellosis.
    • Close contact with animals – and some behaviours in particular – increase the risk of zoonotic transmission.

What should I do if I’m worried about catching a disease from my pet?


    There are a number of good hygiene and pet husbandry practices that can reduce your risk of becoming sick. These include:
    It is especially important for those who are at a higher risk of illness to take precautions to reduce their exposure to zoonotic pathogens. And if you’re thinking about getting a pet, ask your vet which type of animal would best suit your personal circumstances.

    Read more:
    One in three people are infected with _Toxoplasma_ parasite – and the clue could be in our eyes

Immuron Announces FDA Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves way for Clinical Trial Initiation

Retrieved on: 
Monday, May 8, 2023
Volunteering, Institutional review board, Immuron, IMC, US Foods, Campylobacteriosis, Infection, Irritable bowel syndrome, US military watches, Campylobacter, CIR, ETEC, ASX, Enterotoxigenic Escherichia coli, Diarrhea, Judgement, Trial of the century, JHU, Investigational New Drug, Johns Hopkins University, Naval Medical Research Center, Gastroenteritis, Disease, NMRC, Johns, Ethics, Ageing, National Institute of Cholera and Enteric Diseases, FDA, Morale, IND, Food, Safety, Pharmaceutical industry, Vaccine

MELBOURNE, Australia, May 08, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to announce that the US Naval Medical Research Center (NMRC) has received approval from the US Food and Drug Administration (FDA) to proceed with the clinical evaluation of a new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC) developed in collaboration with Immuron. The FDA has removed a clinical hold on the Investigational New Drug (IND) application allowing the NMRC to proceed with its plans to evaluate the efficacy of the hyperimmune product to prevent infectious diarrhoea caused by Campylobacter and ETEC which is now active.

Key Points: 
  • The FDA has removed a clinical hold on the Investigational New Drug (IND) application allowing the NMRC to proceed with its plans to evaluate the efficacy of the hyperimmune product to prevent infectious diarrhoea caused by Campylobacter and ETEC which is now active.
  • The first clinical study will be conducted at the Johns Hopkins University (JHU) Center for Immunization Research (CIR) Inpatient Unit, located at the Johns Hopkins Bayview Medical Campus.
  • Infectious diarrhoea is the most common illness reported by travellers visiting developing countries and among US troops deployed overseas.
  • This release has been authorised by the directors of Immuron Limited.

Immuron US DoD Naval Medical Research Center Submits IND Application for New Campylobacter ETEC Therapeutic

Retrieved on: 
Wednesday, May 11, 2022
Volunteering, Naval Medical Research Center, IND, NASDAQ, GLOBE, IMC, Judgement, Food, Safety, Diarrhea, Campylobacteriosis, Sexual Assault Prevention Response (US military), Disease, Infection, FDA, Gastroenteritis, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, US Foods, Immuron, ETEC, NMRC, Morale, Investigational New Drug, Campylobacter, ASX, Pharmaceutical industry

MELBOURNE, Australia, May 11, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today is pleased to announce that the US Naval Medical Research Center (NMRC) has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration for a new oral therapeutic targeting Campylobacter and ETEC developed in collaboration with Immuron.

Key Points: 
  • US Naval Medical Research Centre (NMRC) submits IND application to the U.S. Food and Drug administration (FDA)
    Two human phase II clinical trials to be conducted.
  • One trial will focus on the ability of the hyperimmune product to prevent infectious diarrhea caused by ETEC and scheduled to be initiated in July 2022.
  • The second trial will focus on protecting volunteers against moderate to severe campylobacteriosis.
  • NMRC is preparing to commence the first of two planned clinical trials in the United States following approval of the application.

The Global Antibiotics Market Will Grow to USD 59,253.24 Million by 2028, at a CAGR of 3.76% - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 15, 2022
Health, General Health, Food and Drug Administration, Bacteria, D, AOM, Economy, Antibiotic sensitivity testing, Development, ASM, Society, Enterobacteriaceae, World, Ill, Geography, Infection, WHO, Bronchitis, Antibiotic, COVID-19, Macrolide, Upper respiratory tract infection, CAGR, Pathogenic bacteria, Pneumonia, Hospital, World Health Organization, Aminoglycoside, Organization, NCBI, Campylobacteriosis, Sulfonamide, 33, Meningitis, Food, Prevalence, Azerbaijan and Organization for Economic Co-operation, Sinusitis, Growth, Death, Diarrhea, Protein, RNA, UNICEF, Genetically modified bacteria, DNA, Poultry, Pharyngitis, Vaccine

The Antibiotics market was valued at US$ 44,111.31 million in 2020 and is projected to reach US$ 59,253.24 million by 2028; it is expected to grow at a CAGR of 3.76% from 2020 to 2028.

Key Points: 
  • The Antibiotics market was valued at US$ 44,111.31 million in 2020 and is projected to reach US$ 59,253.24 million by 2028; it is expected to grow at a CAGR of 3.76% from 2020 to 2028.
  • The growing prevalence of bacterial infection is one of the major factors increasing the demand for antibiotics globally.
  • Such potential increase in prevalence of bacterial infections is expected to continue to drive the growth of antibiotics market during the forecast period.
  • Based on drug class, the antibiotics market is segmented into sulfonamides, aminoglycosides, carbapenem, macrolides, fluoroquinolones, penicillin, cephalosporin, and others.

Immuron Receives A$6.2 Million Award from U.S. DoD to Clinically Evaluate a Military Strength Dosing Regimen for Travelan

Retrieved on: 
Wednesday, January 12, 2022
U.S. government and smoking cessation, Sexual Assault Prevention Response (US military), Research, National Institute of Cholera and Enteric Diseases, Clinical trial, Enterotoxigenic Escherichia coli, Campylobacteriosis, BLA, IMC, Disease, Diarrhea, Licensure, NASDAQ, CEO, U.S. Department of Defense Strategy for Operating in Cyberspace, Volunteering, GLOBE, ASX, CHIM, Campylobacter, Infection, Company, NMRC, Army, Gastroenteritis, USD, ETEC, Morale, Military personnel, Compliance, Judgement, Trial of the century, Pharmaceutical industry, Navy, Defense, Immuron

MELBOURNE, Australia, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce the funding of a new research agreement with the U.S Department of Defense.

Key Points: 
  • This single larger dosing regime is potentially more amenable for use in military populations.
  • Results of the proposed clinical study will also inform on dosing in the pivotal Phase 3 registration trials for BLA licensure.
  • A project kickoff meeting for this award has been scheduled for the end of January with the U.S Government sponsors.
  • A preventative treatment that protects against enteric diseases, is a high priority objective for the US Military.

Meridian Bioscience Receives FDA-Clearance for the Curian® Campy Assay

Retrieved on: 
Wednesday, January 5, 2022
Campylobacter, Health, Development, Food, Dysentery, Patient, Workflow, VIVO, Infection, Fever, Life, Disease, Food and Drug Administration, NASDAQ, Campylobacteriosis, Hospital, FDA, Diagnosis, Nasdaq, Abdominal pain, Solution, Gastrointestinal disease, Pharmaceutical industry, Medical device, Online shopping, Meridian

CINCINNATI, Jan. 5, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that the Curian® Campy assay has received U.S. Food and Drug Administration (FDA) clearance.  The Curian Campy assay is a rapid, qualitative fluorescent immunoassay for the detection of a Campylobacter-specific antigen including C. jejuni, C. coli, C. upsaliensis, and C. lari in human fecal specimens.  The assay was developed to be utilized on the Curian immunofluorescent testing platform. 

Key Points: 
  • The Curian Campy assay is a rapid, qualitative fluorescent immunoassay for the detection of a Campylobacter-specific antigen including C. jejuni, C. coli, C. upsaliensis, and C. lari in human fecal specimens.
  • The Curian Campy assay features an easy workflow and produces objective results in about 20 minutes.
  • Curian Campy offers clinicians accurate and timely results to deliver appropriate care for patients infected with campylobacteriosis.
  • The Curian Analyzer and Curian HpSA assay received FDA clearance in March 2020.

Immuron planned Acquisition of R&D Vaccine Company

Retrieved on: 
Thursday, September 23, 2021
IMC, Infection, NASDAQ, GST, Acquisition, Company, Enterotoxigenic Escherichia coli, ASX, COVID-19, ETEC, Severe acute respiratory syndrome coronavirus 2, Research, Immuron, Campylobacteriosis, GLOBE, Pharmaceutical industry

The Company has been pursuing a major acquisition of a private biotechnology company focused on the development of innovative vaccine technologies.

Key Points: 
  • The Company has been pursuing a major acquisition of a private biotechnology company focused on the development of innovative vaccine technologies.
  • The Immuron Board of Directors considered that this acquisition opportunity would have added significant value to the Company and shareholders potentially delivering a much-needed Australian developed COVID-19 vaccine candidate for commercialization.
  • The ASX has absolute discretion to re-admit a company to the official list after such a transaction has occurred.
  • As a result of Immuron not proceeding with the proposed acquisition at this time.

CDC to Report on Campylobacter Test Results from January 2019 to Date

Retrieved on: 
Monday, December 16, 2019
Pet stores, Medical specialties, Bacterial diseases, Epsilonproteobacteria, Petland, Campylobacteriosis, Campylobacter, Centers for Disease Control and Prevention, Pet store, Health, Medicine

CHILLICOTHE, Ohio, Dec. 16, 2019 /PRNewswire/ -- Petland learned today that the Centers for Disease Control (CDC) will be releasing an update tomorrow in regards tohumancases of Campylobacter infectionsreported between January and November of 2019.

Key Points: 
  • CHILLICOTHE, Ohio, Dec. 16, 2019 /PRNewswire/ -- Petland learned today that the Centers for Disease Control (CDC) will be releasing an update tomorrow in regards tohumancases of Campylobacter infectionsreported between January and November of 2019.
  • The investigation linked this outbreak to contact with pet store puppies and other sources, according to the CDC.
  • Similar to the 2016 outbreak, the specific Campylobacter strain is not originating at any specific Petland store.
  • For information about the course of the illness in people, please visit the CDC website.